Quality of life and healthcare utilisation improvements after atrial fibrillation ablation

Dhiraj Gupta,1 Johan Vijgen,2 Tom De Potter,3 Daniel Scherr,4 Hugo Van Herendael,5 Sebastien Knecht,6 Richard Kobza,7 Benjamin Berte,7 Niels Sandgaard,8 Jean-Paul Albenque,9 Gábor Széplaki,10 Yorick Stevenhagen,11 Philippe Taghji,12 Matt Wright,13 Mattias Duystschaever6

ABSTRACT
Objective Pulmonary vein isolation (PVI) guided by a standardised CLOSE (contiguous optimised lesions) protocol has been shown to increase clinical success after catheter ablation for paroxysmal atrial fibrillation (PAF). This study analysed healthcare utilisation and quality of life (QOL) outcomes from a large multicentre prospective study, measuring association between QOL and atrial fibrillation (AF) burden and identified factors associated with lack of QOL improvement.

Methods CLOSE-guided ablation was performed in 329 consecutive patients (age 61.4 years, 60.8% male) with drug-refractory PAF in 17 European centres. QOL was measured at baseline and 12 months post- ablation via Atrial Fibrillation Effect on Quality of Life Survey (AFEQT) and EuroQOL EQ-5D-5L questionnaires. All-cause and cardiovascular hospitalisations and cardioversions over 12 months pre-ablation and post-ablation were recorded. Rhythm monitoring included weekly and symptom-driven trans-telephonic monitoring, plus ECG and Holter monitoring at 3, 6 and 12 months. AF burden was defined as the percentage of postblanking tracings with an atrial tachyarrhythmia ≥30 s. Continuous measures across multiple time points were analysed using paired t-tests, and associations between various continuous measures were analysed using independent sample t-tests. Each statistical test used two-tailed p-values with a significance level of 0.05.

Results Both QOL instruments showed significant 12-month improvements across all domains: AFEQT score increased 25.1–37.5 points and 33.3%–50.8% fewer patients reporting any problem across EuroQOL EQ-5D-5L domains. Overall, AFEQT improvement was highly associated with AF burden (p=0.009 for <10% vs ≥10% burden, p<0.001 for <20% vs ≥20% burden). Cardiovascular hospitalisations were significantly decreased after ablation (42%, p=0.001). Patients without substantial improvement in AFEQT (55/301, 18.2%) had higher AFEQT and CHA2DS2-VASc scores at baseline, and higher AF burden following PVI.

Conclusions QOL improved and healthcare utilisation decreased significantly after ablation with a standardised CLOSE protocol. QOL improvement was significantly associated with impairment at baseline and AF burden after ablation.

Trial registration number NCT03062046.

INTRODUCTION
Catheter ablation is a widely accepted treatment option for atrial fibrillation (AF). The creation of contiguous and durable lesions during pulmonary vein isolation (PVI) is essential for preventing pulmonary vein (PV) reconnection, thereby reducing the likelihood of subsequent arrhythmia recurrence.1 Arrhythmia recurrences can lead to repeat ablations and increased healthcare utilisation, as well as a reduction in quality of life (QOL).

Radiofrequency lesions can now be optimised with contact force (CF) sensing catheters, providing real-time feedback,2 and utilisation of the CLOSE-PVI protocol has been shown to reduce PV reconnection rates and increase the long-term clinical success of catheter ablation for paroxysmal atrial fibrillation (PAF).3 4 We have recently shown via the multinational prospective VISTAX (Evaluation of Ablation Index and VISITAG™ Use for Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation) study that the CLOSE-PVI workflow is reproducible across multiple centres, with nearly 80% of patients being arrhythmia-free at 12 months postprocedure.5 Prospective data on healthcare utilisation and QOL after PAF ablation with this standardised workflow are limited.

The goals of this study were to report on changes in QOL and healthcare utilisation in the 12 months following catheter ablation for patients in the VISTAX study, and to investigate the relationships between QOL and measures of clinical success, including AF burden. We also sought to identify factors that were associated with lack of significant QOL improvement.

METHODS
Study design and population
We used data collected from the VISTAX study, a prospective, non-randomised, multicentre investigation.3 5 Patients with drug-resistant symptomatic PAF were enrolled between January 2017 and March 2018 at 17 centres across 9 European countries. The research was performed without patient or public involvement.

Ablation procedure
The CLOSE protocol, consisting of CF-guided PVI targeting an interlesion distance ≤6 mm has been previously described.3 5 After transseptal puncture,
a left atrial three-dimensional electroanatomical map was generated using CARTO 3 System with LASSO Circular Mapping Catheter (Biosense Webster, Irvine, California, USA). Ablation was performed with either a Thermocool Smarttouch Catheter or Thermocool Smarttouch SF Catheter (Biosense Webster) to obtain a contiguous lesion set for ipsilateral circumferential PVI. VISITAG SURPOINT target values were 550 for anterior and 400 for posterior. Verification of entrance block was performed for all PVs with the LASSO catheter after a 20 min waiting period.

Follow-up
Postprocedure, a previously ineffective anti-arrhythmic drug (AAD) therapy was permitted to be continued during the 3-month blanking period before being stopped. The use of AADs beyond the blanking period was discouraged. Patients were rigorously monitored for atrial tachyarrhythmia recurrences via weekly and symptom-driven trans-telephonic (TTM) monitoring, as well as 12-lead ECG and 24-hour Holter monitoring at 3, 6 and 12 months postprocedure. Management of recurrences, including repeat ablation(s) during follow-up was per investigator discretion.

Assessment of quality of life and healthcare utilisation

Quality of life
QOL was evaluated at baseline and at the 12-month postprocedure clinic visit. Patients completed two self-administered questionnaires—the Atrial Fibrillation Effect on Quality of Life Survey (AFEQT) and the EuroQoL EQ-5D-5L. The AFEQT is a validated, 20-question disease-specific survey designed to measure patients’ perceptions of their AF symptoms, functional impairment, treatment concerns and satisfaction with treatment. Each question has 7-point Likert responses ranging from the most severe limitations or symptoms to none. The survey produces an overall score and subscale scores for each of three domains: symptoms, daily activities and treatment concerns, with two satisfaction questions scored individually. Each score is normalised to a range of 0–100, with higher scores indicating higher QOL. An increase of 5 points in the overall AFEQT score has been identified as a clinically important difference based on analysis of 1347 patients in an AF registry. The EQ-5D-5L is a simple validated questionnaire used to assess broad health-related QOL in diverse patient populations. One component is a 5-dimension health status comprising 5-level responses to questions on mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The second component is a visual analogue scale (EQ-VAS) for self-evaluation of overall health status on a 20 cm vertical line.

Atrial tachyarrhythmia recurrence and burden
An atrial tachyarrhythmia recurrence was defined as any device-recorded episode of AF, atrial tachycardia (AT) or atrial flutter (AFL) lasting ≥30 s. To evaluate the relationship between postblanking atrial tachyarrhythmia burden and QOL, burden was defined as the percentage of days beyond the 90-day blanking period with at least one device-recorded AF/AT/AFL episode. The denominator used for this percentage was the number of days after the 90-day blanking period that a patient had a tracing. The device recordings used to create this burden end point included core-lab confirmed outcomes from TTM, ECG and Holter monitors, along with AE and postprocedure arrhythmia logs. Overlap among these records was not a concern due to counting each day only once, either as a day with or without burden. For comparisons of patients with higher versus lower burden, cohorts were created by using two cutoffs: burden of <10% vs ≥10% and <20% vs ≥20%.

Healthcare utilisation: hospitalisation, cardioversion and repeat ablation
All-cause hospitalisation, cardiovascular hospitalisation and direct current cardioversion were assessed by comparing 12-month pre-ablation vs 12-month post-ablation rates. Hospitalisations were defined as visits with at least an overnight stay, not concurrent with the ablation procedure. These were further classified as cardiovascular hospitalisations or non-cardiovascular hospitalisations. Repeat ablations were also captured separately without the requirement of an overnight stay.

Statistical methods
Changes in overall AFEQT scores and EQ-VAS scores from baseline to 12 months were summarised for patients who completed questionnaires at both time points. Paired t-tests were used to compare continuous measures across multiple time points, including QOL scores at baseline vs 12 months, and disease-related healthcare utilisations in the 12 months preprocedure versus postprocedure. Independent sample t-tests were used to measure associations between different continuous measures, including average change in overall AFEQT score and clinical success outcomes. McNemar tests were used to compare nominal outcomes, including EQ-5D-5L domains at baseline vs 12 months and the number of patients with at least one all-cause hospitalisation, cardiovascular hospitalisation and cardioversion in the 12-month periods preprocedure versus postprocedure. All statistical tests used two-sided p values and a significance level of 0.05.

Linear regression was used to determine which factors had the greatest impact on a patient’s level of QOL improvement, thus providing insight as to why some patients did not show meaningful gains. One model explored baseline AFEQT scores, patient characteristics and medical history as potential explanatory variables. A separate model explored the impact of post-ablation outcomes, including healthcare utilisation and residual AF burden within 12 months post-ablation. All variables with p values of ≤0.15 in univariate models were tested for inclusion in the multivariable models. Stepwise selection was then used to retain only variables that were significant at a level of 0.10 in the final models.

All statistical analyses were performed using SAS V.9.4 (SAS Institute, Cary, North Carolina, USA).

RESULTS

Patient population
A total of 340 patients were enrolled in the study, with 329 meeting all eligibility criteria, including a CLOSE ablation procedure, as required for the evaluable population. The mean age was 61.4 years and 60.8% were male. Baseline patient characteristics are summarised in table 1.

Quality of life
Of the 329 patients in the evaluable population, 301 (91.5%) had AFEQT questionnaires completed at both baseline and 12 months. The mean overall AFEQT score at baseline was 61.3±20.3, and this increased significantly by 25.7±21.3 points to 87.2±15.2 at 12 months (p<0.001). An increase in AFEQT scores was also observed across each domain and satisfaction question (p<0.001 for each) (figure 1).
Consistent with AFEQT improvement, the mean EQ-VAS score increased by 8.7±14.6 points from 72.7±15.1 at baseline to 81.4±13.8 at 12 months post-ablation (<0.001). In addition, fewer patients reported having problems in each domain of the EQ-5D-5L descriptive questionnaire at 12 months post-procedure relative to baseline, with decreases ranging from 33.3% to 50.8% across the five domains (figure 2). These decreases were statistically significant (<0.001) for all domains except the self-care domain.

Symptomatic atrial tachyarrhythmia recurrence and residual burden
Kaplan-Meier estimated 12-month survival from documented symptomatic atrial tachyarrhythmia recurrence was 82.9% (95% CI 78.8% to 87.0%). Improvement in QOL was significantly associated with residual atrial tachyarrhythmia burden. The mean increase in the overall AFEQT score was higher in patients with <10% burden vs ≥10% (12 points difference, p=0.009) and with further differentiation of patients with <20% burden vs ≥20% (25.0 points difference, p<0.001) (figure 3). Greater improvements in AFEQT scores were also seen in patients who did not require repeat ablation versus those who did (figure 4A), and in patients who did not require post-blanking period cardioversion (figure 4B).

Factors influencing level of improvement in QOL
Using the commonly accepted threshold of ≥5 points increase in overall AFEQT score as reflective of a clinically meaningful improvement in QOL, 246 (81.7%) patients exceeded this threshold while 55 (18.3%) did not. At baseline, the two groups showed no differences in PAF duration, number of failed AADs or presence of coexisting AFL. However, the patients who failed to achieve a clinically meaningful improvement had higher mean overall AFEQT scores at baseline (78.0 vs 57.7, p<0.001), with 52.7% vs 11.4% starting at scores of >80. These patients also had significantly higher CHA2DS2-VASc scores (1.9 vs 1.5, p=0.027) and more required cardioversion within 12 months prior to their ablation (30.9% vs 12.2%, p<0.001).

After ablation, patients without clinically significant improvement in QOL had borderline significantly higher mean residual AF burden (6.5% vs 2.0%, p=0.051), and were almost four times as likely to have had a burden level of ≥20% (10.9% vs 2.8%, p=0.008). In addition, more of these patients tended to have documented arrhythmia recurrence (30.9% vs 19.1%, p=0.053) and more required repeat ablation (18.2% vs 8.1%, p=0.024). They also had higher, but not statistically significant, rates of hospitalisation and cardioversion. All comparisons of baseline characteristics and post-ablation outcomes are shown in table 2.

A scatter plot of the changes from baseline in overall AFEQT score at the 12-month visit versus the baseline scores shows a clear trend of higher improvement in patients with lower QOL at baseline (figure 5). Reductions in the potential level of improvement for patients with high baseline QOL resulted in fewer of these patients experiencing significant levels of improvement compared with patients with moderate or low baseline QOL.

The multivariable linear regression analysis showed that baseline AFEQT score was the most significant baseline predictor of improvement in the overall score at 12 months (<0.001). Every 10-point increase in the baseline overall AFEQT score was significant (p<0.001) except the self-care domain.

### Table 1: Baseline patient characteristics

| Characteristics                          | Evaluable population (n=329) |
|-----------------------------------------|-----------------------------|
| Age, years                              | 61.4±10.0                   |
| Male                                    | 200/329 (60.8)              |
| Body mass index                         | 27.6±4.2                    |
| Left ventricular ejection fraction, %    | 61.6±6.9                    |
| Left atrial diameter, mm                | 39.1±5.2                    |
| CHA2DS2-VASc score                      | 1.6±1.4                     |
| Patient medical history                 |                             |
| Atrial fibrillation duration, months    | 22.0 (6.0, 60.0)            |
| Atrial flutter                          | 63/329 (19.1)               |
| Hypertension                            | 138/329 (41.9)              |
| Type II diabetes                        | 22/329 (6.7)                |
| Coronary disease                        | 34/329 (10.3)               |
| Thromboembolic events                   | 19/329 (5.8)                |
| Congestive heart failure                | 9/329 (2.7)                 |
| NYHA class I                            | 4/329 (1.2)                 |
| NYHA class II                           | 5/329 (1.5)                 |
| Previously failed anti-arrhythmic drug(s)|                         |
| Number of failed anti-arrhythmic drugs  | 1.7±0.7                     |
| Failed any class III anti-arrhythmic drug| 242/329 (73.6)             |
| Failed any class IV anti-arrhythmic drug | 232/329 (70.5)             |

Numbers in the table are represented as mean±SD, n/N (%) or median (IQR). NYHA, New York Heart Association.

### Figure 1

Change in mean Atrial Fibrillation Effect on Quality of Life Survey (AFEQT) scores from baseline to 12 months postprocedure. All score improvements are statistically significant (<0.001). AF, atrial fibrillation.

### Figure 2

EuroQoL EQ-5D-5L change in percentage of patients with problems. Patients with problems include those reporting ‘slight’ or worse level of problem versus ‘none’. All decreases were statistically significant (<0.001) except the self-care domain.

### Figure 3

A scatter plot of the changes from baseline in overall AFEQT score at the 12-month visit versus the baseline scores shows a clear trend of higher improvement in patients with lower QOL at baseline (figure 5). Reductions in the potential level of improvement for patients with high baseline QOL resulted in fewer of these patients experiencing significant levels of improvement compared with patients with moderate or low baseline QOL.
Arrhythmias and sudden death

associated with a mean 7.7-point reduction in score improvement at 1 year (95% CI 6.9 to 8.5, p < 0.001). CHA2DS2-VASc score was the only additional significant predictor in the baseline explanatory model (p = 0.004). Residual atrial tachyarrhythmia burden was the most significant post-ablation predictor of change in QOL (p < 0.001), and no additional post-ablation predictors were significant after adjusting for burden in the post-ablation explanatory model.

Healthcare utilisation: hospitalisation, cardioversion and repeat ablation

The total number of admissions and the number of patients with at least one admission was lower post-procedure for both all-cause and cardiovascular hospitalisations (figure 6). These differences were driven by the cardiovascular hospitalisations, which were reduced by 42.4% (99 to 57, p = 0.001), with a similar reduction in the number of patients having a cardiovascular hospitalisation (37.3%, p = 0.004). The reduction in direct current cardioversions was even greater in magnitude, with the total number decreasing by 62.3% (p < 0.001) and the number of patients requiring cardioversion decreasing by 57.1% (p < 0.001). Repeat ablations accounted for 61.4% of all-cause cardiovascular hospitalisations, representing 33 patients (10.0% of the population) with 35 ablations.

DISCUSSION

Although some data show improvement in hard outcomes such as stroke and overall survival following AF ablation,12 13 the overwhelming reason for offering this treatment remains that of symptom relief. As such, it is important to systematically evaluate changes in AF-related QOL following AF ablation, and to determine factors that are likely to predict the greatest benefit. These data, along with assessment of changes in healthcare utilisation following AF ablation, should help to further improve the already documented health economic benefits from this procedure. To that end, we report multicentre study outcomes of significant reductions in healthcare utilisation and significant increases in patient-reported QOL after ablation for PAF.
Arrhythmias and sudden death using the standardised CLOSE protocol. We observed strong associations between the magnitude of QOL improvement and post-ablation measures of clinical success, including residual AF burden. A small but important group of patients did not experience clinically meaningful improvement in QOL, likely due to either high QOL at baseline or residual AF burden after ablation.

In addition to the impact of AF on a patient’s day-to-day activities, the impact on healthcare resource utilisation can be substantial.14 These findings highlight the need for treatment options that significantly reduce healthcare utilisation in AF populations. In this study, PVI ablation with the CLOSE protocol led to a 1-year reduction in cardiovascular hospitalisations of 42.4% and a 1-year reduction in cardioversions of 62.3%. As healthcare costs continue to rise, these reductions are increasingly important to both healthcare systems and patients.

Another notable aspect of this current study is the use of a broader metric of AF burden to assess the impact of ablation efficacy on QOL improvement. The most widely accepted method is to use an implantable loop recorder,15 16 but this involves

Table 2 Differences between patients with and without significant QOL gains

| Characteristics and outcomes | ≥5 points (n=246) | <5 points (n=55) | P value |
|------------------------------|------------------|-----------------|---------|
| Overall AFEQT score          |                  |                 |         |
| Baseline score               | 57.7±18.4        | 78.0±19.8       | <0.001  |
| High score (>80) at baseline | 28 (11.4)        | 29 (52.7)       | <0.001  |
| 12-month score               | 90.2±11.9        | 73.6±20.9       | <0.001  |
| Change in score—baseline to 12 months | 32.5±17.0     | -4.4±8.9        | <0.001  |
| Characteristics              |                  |                 |         |
| Age, years                   | 61.0±10.1        | 62.9±9.4        | 0.194   |
| Male                         | 156 (63.4)       | 33 (60.0)       | 0.636   |
| Body mass index              | 27.4±4.2         | 28.2±4.5        | 0.226   |
| Left ventricular ejection fraction, % | 61.5±6.7     | 61.2±7.3        | 0.768   |
| Left atrial diameter, mm     | 39.0±5.3         | 39.2±5.1        | 0.845   |
| CHA2DS2-VASc score           | 1.5±1.4          | 1.9±1.4         | 0.027   |
| Patient medical history      |                  |                 |         |
| Atrial fibrillation duration, months | 23.5 (6.0, 60.0) | 20.0 (8.0, 72.0) | 0.652   |
| Atrial flutter               | 48 (19.5)        | 11 (20.0)       | 0.934   |
| Hypertension                 | 96 (39.0)        | 32 (58.2)       | 0.009   |
| Type II diabetes             | 15 (6.1)         | 6 (10.9)        | 0.205   |
| Coronary disease             | 21 (8.5)         | 8 (14.5)        | 0.172   |
| Thromboembolic events        | 14 (5.7)         | 5 (9.1)         | 0.349   |
| Congestive heart failure     | 6 (2.4)          | 3 (5.5)         | 0.235   |
| Utilisation within 12 months pre-ablation |                  |                 |         |
| All-cause hospitalisation    | 58 (23.6)        | 15 (27.3)       | 0.563   |
| Cardiovascular hospitalisation | 55 (22.4)  | 15 (27.3)       | 0.435   |
| Cardioversion                | 30 (12.2)        | 17 (30.9)       | <0.001  |
| Previously failed anti-arrhythmic drug(s) | 1.6±0.8        | 1.7±0.7         | 0.666   |
| Number of failed anti-arrhythmic drugs | 173 (70.3)   | 45 (81.8)       | 0.085   |
| Failed any class VIII anti-arrhythmic drug |                  |                 |         |
| Outcomes within 12 months post-ablation |                  |                 |         |
| Recurrence after 90-day blanking | 47 (19.1)      | 17 (30.9)       | 0.053   |
| Atrial tachyarrhythmia burden | 2.0%±6.7%      | 6.5%±16.5%      | 0.051   |
| Burden of ≥10%               | 16 (6.5)         | 7 (12.7)        | 0.116   |
| Burden of ≥20%               | 7 (2.8)          | 6 (10.9)        | 0.008   |
| Repeat ablation              | 20 (8.1)         | 10 (18.2)       | 0.024   |
| All-cause hospitalisation    | 46 (18.7)        | 14 (25.5)       | 0.257   |
| Cardiovascular hospitalisation | 30 (12.2)   | 11 (20.0)       | 0.127   |
| Cardioversion                | 14 (5.7)         | 5 (9.1)         | 0.349   |

Numbers in the table are represented as mean±SD, n (%) or median (IQR). P values based on t-test for means, Kruskal-Wallis test for medians and χ² test for counts.

AFEQT, Atrial Fibrillation Effect on QualiTy of Life Survey; NYHA, New York Heart Association; QOL, quality of life.

Figure 5 Atrial Fibrillation Effect on Quality of Life Survey (AFEQT) change versus baseline score.

Figure 6 Changes in 12-month all-cause and cardiovascular hospitalisations. Reductions in cardiovascular hospitalisations are statistically significant (p=0.001 for number of admissions, p=0.004 for number of patients with admissions).
additional invasive procedure(s) to implant and/or explant the device, and it carries the risk of false-positive diagnoses because of sensitive arrhythmia detection algorithms. Furthermore, the clinical significance of asymptomatic arrhythmias detected solely on implantable loop recorder is uncertain. Our liberal use of TTM through the 12-month follow-up period in this study allowed us to capture symptomatic arrhythmia recurrences, thereby providing a more focused assessment of clinically relevant arrhythmia burden. Freedom from any episode of AF/AFL/AT of ≥30s duration has been recommended as the definition to use for measuring clinical success at 1 year after AF ablation, and is typically the measure reported in AF ablation studies. However, the current analysis is focused on the overall patient perspective, and our results showed a strong association between residual burden and patient-reported AF-specific QOL improvement, suggesting that it is a meaningful measurement from a patient perspective. Our results are consistent with those of contemporaneous multicentre AF ablation studies. In CABANA, the mean overall AFEQT score in the catheter ablation group improved from 62.9 points at baseline to 86.4 points at 12 months, and in CIRCA-DOSE, the mean overall AFEQT scores in the radiofrequency group improved from 54.1 to 87.5 points at 12 months. Our study shows a similarly impressive improvement of 25.7 points in mean overall score on the AFEQT instrument, underscoring the salutary effects seen with AF catheter ablation. However, the differential impact of this procedure on individual patients’ QOL has not been studied previously. In particular, neither CABANA (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation) nor CIRCA-DOSE (Cryoballoon vs Irrigated Radiofrequency Catheter Ablation: Double Short vs Standard Exposure Duration) reported on patients who derived little or no symptomatic benefit. To this end, our finding that approximately one in six patients did not achieve significant QOL improvement following AF ablation is notable. We have shown that these patients were likely to either be those who had higher levels of QOL at baseline, those with more advanced disease as reflected by higher CHA2DS2-VASc scores or higher residual AF burden following PVI. This latter observation should spur the electrophysiology community towards striving for further improvement in ablation outcomes. Indeed, in this current study, the 12-month success rate of nearing 80% is notably higher compared with prior prospective, multicentre studies with stringent monitoring and independent core laboratory analysis such as FIRE and ICE, where the success rates were 64.1% and 65.6% in the radiofrequency and cryoballoon arms, respectively. Although a supplementary analysis of FIRE and ICE showed that healthcare utilisation rates were lower in the cryoballoon arm in spite of almost identical rates of freedom from arrhythmia, our single-arm study design did not allow such a comparison. Our observation that duration of AF history was the only variable related to freedom from arrhythmia after ablation is important, and is in line with recent publications that support early utilisation of catheter ablation.

LIMITATIONS

The primary limitation of the study was the single-arm design, which can make it difficult to disentangle improvements attributable to treatment from improvements due to a placebo effect. However, the magnitude of QOL improvement was shown to be significantly associated with the objective clinical measure of residual atrial tachyarrhythmia burden, suggesting that any potential placebo effect was not the primary driver of improvement in QOL. Even so, in the absence of a randomised controlled study, and given that the study was powered for efficacy and safety, but not for QOL or healthcare utilisation, our data should be considered as hypothesis-generating. An additional limitation of this study was the absence of continuous rhythm monitoring via an implantable device, which necessitated defining an alternate measure of burden. This definition could potentially be used in other studies of PAF populations, where implantable devices are typically the exception rather than the rule.

CONCLUSION

Our study has demonstrated that patients with PAF with symptomatic AF experience significant increases in QOL, along with corresponding reductions in cardiovascular-related hospitalisation and cardioversion, after ablation with the standardised CLOSE PVI protocol. The magnitude of improvement in QOL was significantly associated with the level of residual AF burden. The minority of patients who did not derive significant symptomatic benefit were more likely to have had a high level of QOL at baseline, and/or were more likely to experience high residual AF burden following ablation.

Key messages

What is already known on this subject?

► Catheter ablation for paroxysmal atrial fibrillation (PAF) improves quality of life (QOL), but factors affecting magnitude of improvement in individual patients are not well described.

What might this study add?

► In this international multicentre study, pulmonary vein isolation with a standardised CLOSE protocol was associated with significant improvement in QOL and healthcare utilisation at 12 months.

► QOL improvement was associated with degree of impairment at baseline and inversely related to the residual AF burden after ablation.

How might this impact on clinical practice?

► Formal QOL assessment at baseline may help identify patients who are more likely to benefit from catheter ablation of PAF.

► Operators should continue to strive towards better ablation outcomes, as patients’ QOL improvement depends on residual arrhythmia burden.

Author affiliations

1Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, UK
2Heart Center, Jessa Hospital, Hasselt, Belgium
3Onze-Lieve-Vrouweziekenhuis, Aalst, Oost-Vlaanderen, Belgium
4Cardiology, Medical University of Graz, Graz, Austria
5Cardiology, Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium
6Department of Cardiology, AZ Sint-Jan AV, Bruges, WVL, Belgium
7Department of Cardiology, Luzerner Kantonsspital, Lucerne, Switzerland
8Department of Cardiology, Odense University Hospital, Odense, Denmark
9Department of Rythmologie, Clinique Pasteur, Toulouse, France
10Laboratory of Echocardiography, Mater Private Hospital, Dublin, Ireland
11Department of Cardiology, Thoraxcentrum, Enschede, The Netherlands
12Department of Cardiology, Clinical Clairval, Marseille, France
13Cardiology, Guys and St Thomas NHS Trust, London, UK

Twitter Dhiraj Gupta @dhirajguptaBHRS

Acknowledgements The authors wish to express their appreciation to all the VISTAX trial investigators. The VISTAX study was sponsored by Biosense Webster. The authors wish to thank the following individuals for their efforts in the execution of the trial, statistical analysis and for providing valuable input/contribution to the development of the article: Nathalie Macours, Carmen Rousseeuw, Sarah Rabau, Lee...
Arrhythmias and sudden death

Ming Boo, Sonia Maccioni, Jaclyn Alcazar, Bharat Kumar Janapala, Larry Gache and Tina Hunter. Medical writing assistance and statistical analysis support was provided by CTI Clinical Trials and Services, Covington, Kentucky, USA.

Contributors All authors provided a substantial contribution to the design, data collection and revision of the work. All authors provided final approval of the version to be published in agreement with ensuring the integrity and accuracy of the work.

Funding This study was funded by Biosense Webster. Dr DG reports grants from Biosense Webster, outside the submitted work.

Competing interests Dr MD reports personal fees (consulting) from Biosense Webster, outside the submitted work; reports non-financial (travel) support for the submitted work. Dr RK reports grants from Biosense Webster, grants from Biotronik, grants from Abbott, grants from Medtronic, grants from Boston, grants from SIS Medical, outside the submitted work. Dr J-GA reports personal fees (consulting) from Biosense Webster and from Abbott outside the submitted work. Drs BB, TDP, SK, NS, DS, YS, PT, HVH, JV and MW have nothing to disclose.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval Study protocol, informed consent and additional study-related documentation were reviewed and approved by the Institutional Review Board and/or Ethics Committee from each study site prior to study enrolment. Written informed consent was received from all study participants before any study procedures took place.

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement Data are available on reasonable request. Johnson & Johnson Medical Devices Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at: http://yoda.yale.edu.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Dhiraj Gupta http://orcid.org/0000-0002-3490-090X
Tom De Potter http://orcid.org/0000-0003-1424-114X
Sebastien Knecht http://orcid.org/0000-0003-4500-0146

REFERENCES
1 Parmar BR, Jarrett TR, Kholmovski EG, et al. Poor scar formation after ablation is associated with atrial fibrillation recurrence. J Interv Card Electrophysiol 2015;44:247–56.
2 Anjaranitha N, Kumar S, Thomas SP, et al. Role of contact force sensing in catheter ablation of cardiac arrhythmias: evolution or history repeating itself? JACC Clin Electrophysiol 2018;4:707–23.
3 Taghji P, El Haddad M, Philips T, et al. Evaluation of a strategy aiming to enclose the pulmonary veins with contiguous and optimized radiofrequency lesions in paroxysmal atrial fibrillation: a pilot study. JACC Clin Electrophysiol 2018;4:99–108.
4 Philips T, Taghji P, El Haddad M, et al. Improving procedural and one-year outcome after contact force-guided pulmonary vein isolation: the role of interlesion distance, ablation index, and contact force variability in the ‘CLOSE’-protocol. Europace 2018;20:1419–27.
5 Duytschaever M, Vijgen J, De Potter T, et al. Standardized pulmonary vein isolation workflow to enclose veins with contiguous lesions: the multicenter VISTA trial. Europace. In Press 2020.
6 Spertus J, Dorian P, Buben R, et al. Development and validation of the atrial fibrillation effect on quality-of-life (AFEQT) questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2011;4:15–25.
7 Atrial fibrillation effect on quality of life (AFEQT) questionnaire instruction and scoring manual 2009.
8 Holmes DN, Piccini JP, Allen LA, et al. Defining clinically important difference in the atrial fibrillation effect on quality of life score. Circ Cardiovasc Qual Outcomes 2019;12:e005358.
9 Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36.
10 Foundation ER. EQ-5D-5L user guide: basic information on how to use the EQ-5D-5L instrument, 2015.
11 Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417–27.
12 Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control therapy in patients with atrial fibrillation. N Engl J Med 2020.
13 Kim MH, Johnston SS, Chu B-C, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011;4:313–20.
14 Duytschaever M, De Potter J, Demolder A, et al. Long-Term impact of catheter ablation on arrhythmia burden in low-risk patients with paroxysmal atrial fibrillation: the close to cure study. Heart Rhythm 2020;17:535–43.
15 Andrade JG, Mace L, Verma A, et al. Quality of life and health care utilization in the CIRCA-DOSE study. JACC Clin Electrophysiol 2020;6:935–44.
16 Alfa M, Meese J, Koppert T, et al. Incidence of false-positive transmissions during remote rhythm monitoring with implantable loop recorders. Heart Rhythm 2020;17:75–80.
17 Calkins H, Hindricks G, Cappato R, et al. HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Heart Rhythm 2017;14:e445–94.
18 Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019;321:1275–85.
19 Chun KRL, Brugada J, Elehan A, et al. The impact of Cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation on healthcare utilization and costs: an economic analysis from the fire and ice trial. J Am Heart Assoc 2017;6:e006043.
20 Kirchhof P, Camm AJ, Goette A, et al. EAST-AFNET 4 trial Investigators. early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305–16.
21 Andrade JG, Wells GA, Dewell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 2021;384:305–15.